Nicole E. Scangarella-Oman, MS

Scientific Director
GlaxoSmithKline plc.

Disclosure(s): GlaxoSmithKline plc.: Employee and shareholder

Poster(s):

• 641 - Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Resistant to Commonly Used Oral Therapies for UTI in the US (2019-2020)
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 1675 - Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 2225 - Analysis of Co-Resistance Among Escherichia coli Urine Isolates From Female Outpatients in the United States
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 2226 - Analysis of Co-Resistance Among Klebsiella pneumoniae Urine Isolates From Female Outpatients in the United States
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 2227 - Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients With Urine Klebsiella pneumoniae Isolates: A Multicenter Evaluation
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET